Medication info
Combirrocan Tablet 20/32 mg

Combirrocan Tablet 20/32 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702404 · Approved 2017.05.16 · Insurance code 657203120

Summary

Main use
Treatment of hypertension, heart failure, and dyslipidemia; suppression of atherosclerosis and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and patient response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, heart failure, and dyslipidemia; suppression of atherosclerosis and prevention of cardiovascular disease

  • Essential hypertension
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is a medicine that replaces or complements ACE inhibitors in the treatment of essential hypertension and in heart failure patients with impaired left ventricular function. Rosuvastatin is used as an adjunct to diet in patients with hyperlipidemia, notably familial hypercholesterolemia and mixed hyperlipidemia. Additionally, Rosuvastatin helps to slow the progression of atherosclerosis and reduces the risk of stroke, myocardial infarction, and vascular revascularization in patients at high cardiovascular risk. The combination of these two medications enhances cardiovascular health and effectively manages blood pressure and cholesterol levels, improving the patient's condition.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and patient response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause severe harm to the fetus and newborns during pregnancy, so it must be stopped immediately if pregnancy is confirmed. It should not be used in individuals with allergies to this medicine or its components, in individuals with severely compromised liver function, pregnant or nursing women, and those with certain vascular diseases or significantly impaired kidney function. Careful usage is required in elderly patients, patients with high serum potassium, and those with liver function impairment, making regular monitoring of liver function tests and serum potassium levels particularly important. Symptoms such as muscle pain or weakness may occur; if these symptoms arise, consult a doctor immediately, and treatment may need to be discontinued in severe cases. This medication can interact with other drugs; caution is needed when taken with potassium-sparing diuretics, certain antibiotics, antifungals, etc. Pregnant or nursing women should not take this medication, and women of childbearing potential should use appropriate contraception. Safety and efficacy in children have not been established, therefore it is not recommended. In case of overdose, appropriate treatment is needed based on symptoms, and this medication is not removed by dialysis. Caution is advised while driving or operating machinery due to possible dizziness or fatigue. Store in a tightly sealed container, out of reach of children, and in its original packaging for safety.

Side effects

Headache, nasopharyngitis, local infections, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, dizziness, orthostatic dizziness, xanthelasma, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, nausea, increased blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, dizziness, paresthesia, dyspepsia, gastritis, tachycardia, palpitations, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, cold sweat, hand tremor, decreased concentration, convulsions, altered consciousness, increased liver enzyme levels, hepatitis, jaundice, vascular edema, vascular edema (swelling of the face, lips, tongue, throat, etc.), rhabdomyolysis, arthralgia, low back pain, kidney function impairment, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbances, decreased libido, forgetfulness, decreased appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, abdominal pain, pancreatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, thrombocytopenia, jaundice, hepatitis, fever, resolution, dyspnea, abnormal chest X-ray findings, increased blood pressure, worsening blood pressure, unstable angina, pneumonia, femoral fracture, contusion, idiopathic pulmonary fibrosis, vertigo, orthostatic vertigo, adrenal insufficiency, hypotension, hyperkalemia, kidney function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, increased ALT, increased AST, increased γ-GTP, increased serum CK, elevated serum and urine myoglobin, myalgia, myopathy, rhabdomyolysis, headache, dizziness, itching, nausea, weakness, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, decreased appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.